Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice

Sarris, 2012, The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study, Hum Psychopharmacol, 27, 262, 10.1002/hup.2216 Fu, 2008, Toxicity of kava kava, J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev, 26, 89, 10.1080/10590500801907407 Jamieson, 1990, The antinociceptive actions of kava components IN mice, Clin Exp Pharmacol Physiol, 17, 495, 10.1111/j.1440-1681.1990.tb01349.x Cairney, 2002, The neurobehavioural effects of kava, Aust N Z J Psychiatr, 36, 657, 10.1046/j.1440-1614.2002.01027.x Schelosky, 1995, Kava and dopamine antagonism, J Neurol Neurosurg Psychiatry, 58, 639, 10.1136/jnnp.58.5.639 Liu, 2018, Single-lab validation for determination of kavalactones and flavokavains in piper methysticum (kava), Planta Med, 84, 1213, 10.1055/a-0637-2400 Singh, 2002, Therapeutic potential of kava in the treatment of anxiety disorders, CNS Drugs, 16, 731, 10.2165/00023210-200216110-00002 Krum, 2020, Kava decreases the stereotyped behavior induced by amphetamine in mice, J Ethnopharmacol, 265, 113293, 10.1016/j.jep.2020.113293 Sarris, 2011, Kava: a comprehensive review of efficacy, safety, and psychopharmacology, Aust N Z J Psychiatr, 45, 27, 10.3109/00048674.2010.522554 Uebelhack, 1998, Inhibition of platelet MAO-B by kava pyrone-enriched extract from piper methysticum forster (kava-kava), Pharmacopsychiatry, 31, 187, 10.1055/s-2007-979325 Blazevic, 2017, Chronic postnatal monoamine oxidase inhibition affects affiliative behavior in rat pupso, Pharmacol Biochem Behav, 153, 60, 10.1016/j.pbb.2016.12.008 Edmondson, 2009, Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases, Biochemistry, 48, 4220, 10.1021/bi900413g Cohen, 2002, Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow, Proc Natl Acad Sci Unit States Am, 94, 4890, 10.1073/pnas.94.10.4890 Li, 2014, A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models, Nat Commun, 5, 3276, 10.1038/ncomms4276 Vindis, 2001, Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase, Kidney Int, 59, 76, 10.1046/j.1523-1755.2001.00468.x Bach, 1988, cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties, Proc Natl Acad Sci U S A, 85, 4934, 10.1073/pnas.85.13.4934 Finberg, 2016, Inhibitors of MAO-A and MAO-B in psychiatry and neurology, Front Pharmacol, 7, 340, 10.3389/fphar.2016.00340 Youdim, 2006, Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness, Br J Pharmacol, 147, S287, 10.1038/sj.bjp.0706464 Youdim, 2006, The therapeutic potential of monoamine oxidase inhibitors, Nat Rev Neurosci, 7, 295, 10.1038/nrn1883 Saura, 1997, Biphasic and region-specific MAO-B response to aging in normal human brain, Neurobiol Aging, 18, 497, 10.1016/S0197-4580(97)00113-9 Reagan-Shaw, 2007, Dose translation from animal to human studies revisited, Faseb J, 22, 659, 10.1096/fj.07-9574LSF Behl, 2011, Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava, Food Chem Toxicol, 49, 2820, 10.1016/j.fct.2011.07.067 Anchan, 2014, GPR30 activation decreases anxiety in the open field test but not in the elevated plus maze test in female mice, Brain Behav, 4, 51, 10.1002/brb3.197 Fachinetto, 2007, Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter, Prog Neuro-Psychopharmacol Biol Psychiatry, 31, 1478, 10.1016/j.pnpbp.2007.06.028 Busanello, 2011, Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice, Behav Pharmacol, 22, 71, 10.1097/FBP.0b013e328341e9b4 Figueira, 2015, Effects of diphenyl diselenide on behavioral and biochemical changes induced by amphetamine in mice, J Neural Transm, 122, 201, 10.1007/s00702-014-1257-4 Lowry, 1951, Protein assay, J Biol Chem, 193, 265, 10.1016/S0021-9258(19)52451-6 Morinan, 1985, An improved fluorimetric assay for brain monoamine oxidase, J Pharmacol Methods, 13, 213, 10.1016/0160-5402(85)90021-X Busanello, 2017, Resveratrol protects against vacuous chewing movements induced by chronic treatment with Fluphenazine, Neurochem Res, 42, 3033, 10.1007/s11064-017-2335-4 Soto-Otero, 2001, Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals potential implications in relation to oxidative stress, Life Sci, 69, 879, 10.1016/S0024-3205(01)01178-X Villarinho, 2012, Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice, Prog Neuro-Psychopharmacol Biol Psychiatry, 39, 31, 10.1016/j.pnpbp.2012.04.007 de Oliveira, 2015, Silymarin has antioxidant potential and changes the activity of Na+/K+-ATPase and monoamine oxidase in vitro, Ind Crop Prod, 70, 347, 10.1016/j.indcrop.2015.03.060 Harfenist, 1996, Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups, J Med Chem, 39, 1857, 10.1021/jm950595m Reinheimer, 2020, Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis, Naunyn-Schmiedeberg’s Arch Pharmacol, 393, 2439, 10.1007/s00210-020-01923-0 Johns, 1993, Kava: the Pacific drug. Psychoactive plants of the World. Vincent Lebot , Mark Merlin , Lamont Lindstrom, Q Rev Biol, 256 Blumenthal, 2005, Kava: from Ethnology to Ethnopharmacology By Yadhu N. Singh (South Dakota State University). CRC Press, Boca Raton. 2004. vii +167 pp. 7 × 10 1/4 in. $99.95. ISBN 3-415-32327-4, J Nat Prod, 68, 152, 10.1021/np030775w Cawte, 1986, Parameters of kava used as a challenge to alcohol, Aust N Z J Psychiatr, 20, 70, 10.3109/00048678609158867 Sarris, 2009, Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum, Compl Ther Med, 17, 176, 10.1016/j.ctim.2009.01.001 Lebot, 2014, Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC), Food Chem, 151, 554, 10.1016/j.foodchem.2013.11.120 Teschke, 2011, Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits, Dig Liver Dis, 43, 676, 10.1016/j.dld.2011.01.018 Abu, 2013, The flavokawains: uprising medicinal chalcones, Canc Cell Int, 13, 102, 10.1186/1475-2867-13-102 Prinsloo, 2019, Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum), Planta Med, 85, 1136 Mathew, 2014, Plant Secondary Metabolites- Potent Inhibitors of Monoamine Oxidase Isoforms, Cent Nerv Syst Agents Med Chem, 14, 28, 10.2174/1871524914666140826111930 Sällström Baum, 1998, Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats, Prog Neuro-Psychopharmacol Biol Psychiatry, 22, 1105, 10.1016/S0278-5846(98)00062-1 Chua, 2016, Kavain, the major constituent of the anxiolytic kava extract, potentiates gabaa receptors: Functional characteristics and molecular mechanism, PLoS One, 11, 10.1371/journal.pone.0157700 Dinh, 2001, Interaction of various Piper methysticum cultivars with CNS receptors in vitro, Planta Med, 67, 306, 10.1055/s-2001-14334 Wang, 2014, Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease, Eur J Med Chem, 80, 543, 10.1016/j.ejmech.2014.04.078 Youdim, 2004, Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases, J Neural Transm, 111, 1455, 10.1007/s00702-004-0143-x Di Giovanni, 2016, Monoaminergic and histaminergic strategies and treatments in brain diseases, Front Neurosci, 10, 541, 10.3389/fnins.2016.00541 Kim, 2016, Close correlation of monoamine oxidase activity with progress of Alzheimer's disease in mice, observed by in vivo two-photon imaging, ACS Cent Sci, 2, 967, 10.1021/acscentsci.6b00309 Lieu, 2013, Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson's Disease, PLoS One, 8, 10.1371/journal.pone.0054200 Tripathi, 2019, Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update, Med Res Rev, 39, 1603, 10.1002/med.21561 Dezsi, 2017, Monoamine Oxidase B Inhibitors in Parkinson's Disease, CNS Neurol Disord - Drug Targets, 16, 425, 10.2174/1871527316666170124165222 Guglielmi, 2020, Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors, Eur J Med Chem, 205, 112650, 10.1016/j.ejmech.2020.112650 Mathew, 2020, Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment, Comb Chem High Throughput Screen, 23, 842, 10.2174/1386207323999200728122627 Wang, 2020, Behavioral and physiological effects of acute and chronic kava exposure in adult zebrafish, Neurotoxicol Teratol, 79, 106881, 10.1016/j.ntt.2020.106881 Singh, 1992, Kava: an overview, J Ethnopharmacol, 37, 13, 10.1016/0378-8741(92)90003-A Roze, 2010, Huntington's disease, Adv Exp Med Biol, 685, 45, 10.1007/978-1-4419-6448-9_5 Bortolato, 2009, Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase b-deficient mice, Neuropsychopharmacology, 34, 2746, 10.1038/npp.2009.118 Volgin, 2020, DARK Classics in Chemical Neuroscience: Kava, ACS Chem Neurosci, 11, 3893, 10.1021/acschemneuro.9b00587